Plasmidic qnrA3 enhances Escherichia coli fitness in absence of antibiotic exposure

PLoS ONE

Volumn 6, Issue 9, 2011, Pages

  Michon, Adrien ^a   Allou, Nicolas ^a   Chau, Françoise ^a   Podglajen, Isabelle ^b   Fantin, Bruno ^a,c   Cambau, Emmanuelle ^a,d  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^c BEAUJON HOSPITAL   (France)

^d SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL GROWTH; BACTERIUM ISOLATE; COLONY FORMING UNIT; CONTROLLED STUDY; ESCHERICHIA COLI; FEMALE; FLOW CYTOMETRY; GENE DELETION; GENE EXPRESSION PROFILING; GENE FUNCTION; GENETIC STABILITY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; NUCLEOTIDE SEQUENCE; PLASMID; PYELONEPHRITIS; QNRA3 GENE; SPECTROPHOTOMETRY; ANIMAL; CBA MOUSE; DRUG EFFECT; GENETICS; METABOLISM; MICROBIOLOGY; PATHOGENICITY; PHYSIOLOGY; URINARY TRACT INFECTION;

BACTERIA (MICROORGANISMS); ESCHERICHIA COLI;

ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; QUINOLONE DERIVATIVE;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; ESCHERICHIA COLI; FEMALE; FLOW CYTOMETRY; MICE; MICE, INBRED CBA; PLASMIDS; QUINOLONES; URINARY TRACT INFECTIONS;

EID: 80052524989     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0024552     Document Type: Article

References (70)

1. Hooper DC, (2000) Mechanisms of action and resistance of older and newer fluoroquinolones. Clin Infect Dis 31 (Suppl 2): S24-28.
2. Heisig P, (2009) Type II topoisomerases-inhibitors, repair mechanisms and mutations. Mutagenesis 24: 465-469.
3. Goossens H, (2009) Antibiotic consumption and link to resistance. Clin Microbiol Infect 15 (Suppl 3): 12-15.
4. Garau J, Xercavins M, Rodriguez-Carballeira M, Gomez-Vera JR, Coll I, et al. (1999) Emergence and dissemination of quinolone-resistant Escherichia coli in the community. Antimicrob Agents Chemother 43: 2736-2741.
5. Jacoby GA, (2005) Mechanisms of resistance to quinolones. Clin Infect Dis 41 (Suppl 2): S120-126.
6. Martinez-Martinez L, Pascual A, Jacoby GA, (1998) Quinolone resistance from a transferable plasmid. Lancet 351: 797-799.
7. Tran JH, Jacoby GA, (2002) Mechanism of plasmid-mediated quinolone resistance. Proc Natl Acad Sci U S A 99: 5638-5642.
8. Robicsek A, Strahilevitz J, Jacoby GA, Macielag M, Abbanat D, et al. (2006) Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase. Nat Med 12: 83-88.
9. Yamane K, Wachino J, Suzuki S, Kimura K, Shibata N, et al. (2007) New plasmid-mediated fluoroquinolone efflux pump, QepA, found in an Escherichia coli clinical isolate. Antimicrob Agents Chemother 51: 3354-3360.
10. Strahilevitz J, Jacoby GA, Hooper DC, Robicsek A, (2009) Plasmid-mediated quinolone resistance: a multifaceted threat. Clin Microbiol Rev 22: 664-689.
11. Cambau E, Lascols C, Sougakoff W, Bebear C, Bonnet R, et al. (2006) Occurrence of qnrA-positive clinical isolates in French teaching hospitals during 2002-2005. Clin Microbiol Infect 12: 1013-1020.
12. Wang M, Sahm DF, Jacoby GA, Zhang Y, Hooper DC, (2004) Activities of newer quinolones against Escherichia coli and Klebsiella pneumoniae containing the plasmid-mediated quinolone resistance determinant qnr. Antimicrob Agents Chemother 48: 1400-1401.
13. Allou N, Cambau E, Massias L, Chau F, Fantin B, (2009) Impact of low-level resistance to fluoroquinolones due to qnrA1 and qnrS1 genes or a gyrA mutation on ciprofloxacin bactericidal activity in a murine model of Escherichia coli urinary tract infection. Antimicrob Agents Chemother 53: 4292-4297.
14. Rodriguez-Martinez JM, Pichardo C, Garcia I, Pachon-Ibanez ME, Docobo-Perez F, et al. (2008) Activity of ciprofloxacin and levofloxacin in experimental pneumonia caused by Klebsiella pneumoniae deficient in porins, expressing active efflux and producing QnrA1. Clin Microbiol Infect 14: 691-697.
15. Cattoir V, Poirel L, Mazel D, Soussy CJ, Nordmann P, (2007) Vibrio splendidus as the source of plasmid-mediated QnrS-like quinolone resistance determinants. Antimicrob Agents Chemother 51: 2650-2651.
16. Lascols C, Podglajen I, Verdet C, Gautier V, Gutmann L, et al. (2008) A plasmid-borne Shewanella algae Gene, qnrA3, and its possible transfer in vivo between Kluyvera ascorbata and Klebsiella pneumoniae. J Bacteriol 190: 5217-5223.
17. Poirel L, Liard A, Rodriguez-Martinez JM, Nordmann P, (2005) Vibrionaceae as a possible source of Qnr-like quinolone resistance determinants. J Antimicrob Chemother 56: 1118-1121.
18. Poirel L, Rodriguez-Martinez JM, Mammeri H, Liard A, Nordmann P, (2005) Origin of plasmid-mediated quinolone resistance determinant QnrA. Antimicrob Agents Chemother 49: 3523-3525.
19. Tran JH, Jacoby GA, Hooper DC, (2005) Interaction of the plasmid-encoded quinolone resistance protein Qnr with Escherichia coli DNA gyrase. Antimicrob Agents Chemother 49: 118-125.
20. Tran JH, Jacoby GA, Hooper DC, (2005) Interaction of the plasmid-encoded quinolone resistance protein QnrA with Escherichia coli topoisomerase IV. Antimicrob Agents Chemother 49: 3050-3052.
21. Merens A, Matrat S, Aubry A, Lascols C, Jarlier V, et al. (2009) The pentapeptide repeat proteins MfpAMt and QnrB4 exhibit opposite effects on DNA gyrase catalytic reactions and on the ternary gyrase-DNA-quinolone complex. J Bacteriol 191: 1587-1594.
22. Hegde SS, Vetting MW, Roderick SL, Mitchenall LA, Maxwell A, et al. (2005) A fluoroquinolone resistance protein from Mycobacterium tuberculosis that mimics DNA. Science 308: 1480-1483.
23. Hegde SS, Vetting MW, Mitchenall LA, Maxwell A, Blanchard JS, (2011) Structural and biochemical analysis of the pentapeptide repeat protein EfsQnr, a potent DNA gyrase inhibitor. Antimicrob Agents Chemother 55: 110-117.
24. Xiong X, Bromley EH, Oelschlaeger P, Woolfson DN, Spencer J, (2011) Structural insights into quinolone antibiotic resistance mediated by pentapeptide repeat proteins: conserved surface loops direct the activity of a Qnr protein from a Gram-negative bacterium. Nucleic Acids Res 39: 3917-3927.
25. Vetting MW, Hegde SS, Wang M, Jacoby GA, Hooper DC, et al. (2011) Structure of QnrB1, a plasmid-mediated fluoroquinolone resistance factor. J Biol Chem 10.1074/jbc.M111.226936.
26. Andersson DI, Hughes D, (2010) Antibiotic resistance and its cost: is it possible to reverse resistance? Nat Rev Microbiol 8: 260-271.
27. Heisig P, Tschorny R, (1994) Characterization of fluoroquinolone-resistant mutants of Escherichia coli selected in vitro. Antimicrob Agents Chemother 38: 1284-1291.
28. Komp Lindgren P, Marcusson LL, Sandvang D, Frimodt-Moller N, Hughes D, (2005) Biological cost of single and multiple norfloxacin resistance mutations in Escherichia coli implicated in urinary tract infections. Antimicrob Agents Chemother 49: 2343-2351.
29. Marcusson LL, Frimodt-Moller N, Hughes D, (2009) Interplay in the selection of fluoroquinolone resistance and bacterial fitness. PLoS Pathog 5: e1000541.
30. Morosini MI, Ayala JA, Baquero F, Martinez JL, Blazquez J, (2000) Biological cost of AmpC production for Salmonella enterica serotype Typhimurium. Antimicrob Agents Chemother 44: 3137-3143.
31. Luo N, Pereira S, Sahin O, Lin J, Huang S, et al. (2005) Enhanced in vivo fitness of fluoroquinolone-resistant Campylobacter jejuni in the absence of antibiotic selection pressure. Proc Natl Acad Sci U S A 102: 541-546.
32. Welch RA, Burland V, Plunkett G 3rd, Redford P, Roesch P, et al. (2002) Extensive mosaic structure revealed by the complete genome sequence of uropathogenic Escherichia coli. Proc Natl Acad Sci U S A 99: 17020-17024.
33. Labat F, Pradillon O, Garry L, Peuchmaur M, Fantin B, et al. (2005) Mutator phenotype confers advantage in Escherichia coli chronic urinary tract infection pathogenesis. FEMS Immunol Med Microbiol 44: 317-321.
34. Shaw KJ, Rather PN, Hare RS, Miller GH, (1993) Molecular genetics of aminoglycoside resistance genes and familial relationships of the aminoglycoside-modifying enzymes. Microbiol Rev 57: 138-163.
35. Cesaro A, Bettoni RR, Lascols C, Merens A, Soussy CJ, et al. (2008) Low selection of topoisomerase mutants from strains of Escherichia coli harbouring plasmid-borne qnr genes. J Antimicrob Chemother 61: 1007-1015.
36. Wang M, Tran JH, Jacoby GA, Zhang Y, Wang F, et al. (2003) Plasmid-mediated quinolone resistance in clinical isolates of Escherichia coli from Shanghai, China. Antimicrob Agents Chemother 47: 2242-2248.
37. Liassine N, Zulueta-Rodriguez P, Corbel C, Lascols C, Soussy CJ, et al. (2008) First detection of plasmid-mediated quinolone resistance in the community setting and in hospitalized patients in Switzerland. J Antimicrob Chemother 62: 1151-1152.
38. Schrag SJ, Perrot V, (1996) Reducing antibiotic resistance. Nature 381: 120-121.
39. Paulander W, Maisnier-Patin S, Andersson DI, (2009) The fitness cost of streptomycin resistance depends on rpsL mutation, carbon source and RpoS (sigmaS). Genetics 183: 539-546 531SI-532SI.
40. Lee SW, Edlin G, (1985) Expression of tetracycline resistance in pBR322 derivatives reduces the reproductive fitness of plasmid-containing Escherichia coli. Gene 39: 173-180.
41. Nguyen TN, Phan QG, Duong LP, Bertrand KP, Lenski RE, (1989) Effects of carriage and expression of the Tn10 tetracycline-resistance operon on the fitness of Escherichia coli K12. Mol Biol Evol 6: 213-225.
42. Balsalobre L, de la Campa AG, (2008) Fitness of Streptococcus pneumoniae fluoroquinolone-resistant strains with topoisomerase IV recombinant genes. Antimicrob Agents Chemother 52: 822-830.
43. Hurdle JG, O'Neill AJ, Chopra I, (2004) The isoleucyl-tRNA synthetase mutation V588F conferring mupirocin resistance in glycopeptide-intermediate Staphylococcus aureus is not associated with a significant fitness burden. J Antimicrob Chemother 53: 102-104.
44. Petersen A, Aarestrup FM, Olsen JE, (2009) The in vitro fitness cost of antimicrobial resistance in Escherichia coli varies with the growth conditions. FEMS Microbiol Lett 299: 53-59.
45. Rozen DE, McGee L, Levin BR, Klugman KP, (2007) Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother 51: 412-416.
46. Bagel S, Hullen V, Wiedemann B, Heisig P, (1999) Impact of gyrA and parC mutations on quinolone resistance, doubling time, and supercoiling degree of Escherichia coli. Antimicrob Agents Chemother 43: 868-875.
47. Bemer P, Corvec S, Guitton C, Giraudeau C, Le Gargasson G, et al. (2007) Biological cost of fluoroquinolone resistance in Escherichia coli implicated in polyclonal infection. Pathol Biol (Paris) 55: 288-291.
48. Johnson CN, Briles DE, Benjamin WH Jr, Hollingshead SK, Waites KB, (2005) Relative fitness of fluoroquinolone-resistant Streptococcus pneumoniae. Emerg Infect Dis 11: 814-820.
49. Kugelberg E, Lofmark S, Wretlind B, Andersson DI, (2005) Reduction of the fitness burden of quinolone resistance in Pseudomonas aeruginosa. J Antimicrob Chemother 55: 22-30.
50. De Gelder L, Ponciano JM, Joyce P, Top EM, (2007) Stability of a promiscuous plasmid in different hosts: no guarantee for a long-term relationship. Microbiology 153: 452-463.
51. Mnif B, Vimont S, Boyd A, Bourit E, Picard B, et al. (2010) Molecular characterization of addiction systems of plasmids encoding extended-spectrum beta-lactamases in Escherichia coli. J Antimicrob Chemother 65: 1599-1603.
52. Rossolini GM, D'Andrea MM, Mugnaioli C, (2008) The spread of CTX-M-type extended-spectrum beta-lactamases. Clin Microbiol Infect 14 (Suppl 1): 33-41.
53. Jacoby GA, Munoz-Price LS, (2005) The new beta-lactamases. N Engl J Med 352: 380-391.
54. Skippington E, Ragan MA, (2011) Lateral genetic transfer and the construction of genetic exchange communities. FEMS Microbiol Rev 35 10.1111/j.1574-6976.2010.00261.x.
55. Hooper D, (2003) Mechanisms of quinolone resistance. In: Hooper D, Rubinstein E, editors. Quinolone antimicrobial agents Washington DC ASM press pp. 41-67.
56. Poole K, (2005) Efflux-mediated antimicrobial resistance. J Antimicrob Chemother 56: 20-51.
57. Begot CDI, Daudin JD, Labadie JC, Lebert A, (1996) Recommendations for calculating growth parameters by optical density measurements. Journal of Microbiological Methods pp. 225-232.
58. Cavaco LM, Hasman H, Xia S, Aarestrup FM, (2009) qnrD, a novel gene conferring transferable quinolone resistance in Salmonella enterica serovar Kentucky and Bovismorbificans strains of human origin. Antimicrob Agents Chemother 53: 603-608.
59. Tamtam F, Mercier F, Le Bot B, Eurin J, Tuc Dinh Q, et al. (2008) Occurrence and fate of antibiotics in the Seine River in various hydrological conditions. Sci Total Environ 393: 84-95.
60. Wang M, Sahm DF, Jacoby GA, Hooper DC, (2004) Emerging plasmid-mediated quinolone resistance associated with the qnr gene in Klebsiella pneumoniae clinical isolates in the United States. Antimicrob Agents Chemother 48: 1295-1299.
61. Robicsek A, Jacoby GA, Hooper DC, (2006) The worldwide emergence of plasmid-mediated quinolone resistance. Lancet Infect Dis 6: 629-640.
62. Robicsek A, Strahilevitz J, Sahm DF, Jacoby GA, Hooper DC, (2006) qnr prevalence in ceftazidime-resistant Enterobacteriaceae isolates from the United States. Antimicrob Agents Chemother 50: 2872-2874.
63. Arsene S, Leclercq R, (2007) Role of a qnr-like gene in the intrinsic resistance of Enterococcus faecalis to fluoroquinolones. Antimicrob Agents Chemother 51: 3254-3258.
64. Bolivar F, Rodriguez RL, Greene PJ, Betlach MC, Heyneker HL, et al. (1977) Construction and characterization of new cloning vehicles. II. A multipurpose cloning system. Gene 2: 95-113.
65. Watson N, (1988) A new revision of the sequence of plasmid pBR322. Gene 70: 399-403.
66. Mammeri H, Van De Loo M, Poirel L, Martinez-Martinez L, Nordmann P, (2005) Emergence of plasmid-mediated quinolone resistance in Escherichia coli in Europe. Antimicrob Agents Chemother 49: 71-76.
67. Wang G, Whittam TS, Berg CM, Berg DE, (1993) RAPD (arbitrary primer) PCR is more sensitive than multilocus enzyme electrophoresis for distinguishing related bacterial strains. Nucleic Acids Res 21: 5930-5933.
68. Warringer J, Blomberg A, (2003) Automated screening in environmental arrays allows analysis of quantitative phenotypic profiles in Saccharomyces cerevisiae. Yeast 20: 53-67.
69. Chau F, Lefort A, Benadda S, Dubee V, Fantin B, (2011) Flow cytometry as a tool to determine the effects of cell wall-active antibiotics on vancomycin-susceptible and resistant Enteroroccus faecalis. Antimicrob Agents Chemother 55: 395-398.
70. Pinder AC, Purdy PW, Poulter SA, Clark DC, (1990) Validation of flow cytometry for rapid enumeration of bacterial concentrations in pure cultures. J Appl Bacteriol 69: 92-100.